elenbecestat (E2609) / Biogen, Eisai 
Welcome,         Profile    Billing    Logout  

1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elenbecestat (E2609) / Eisai, Biogen
MissionAD2, NCT03036280 / 2016-004128-42: A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_

Not Appicable Apr 2021 - Jun 2021 : From MISSION AD2 trial in Alzheimer's disease (trial terminated)
Not Appicable Mar 2019 - Mar 2019 : Enrollment completion of P3 MISSION AD1 and MISSION AD2 trials (trial terminated)
Active, not recruiting
3
1018
Europe, Canada, Japan, US, RoW
Elenbecestat (E2609), Elenbecestat, Placebo
Eisai Co., Ltd., Biogen
Alzheimer's Disease
11/23
11/23

Download Options